alnylam pharmaceuticals glp-1 receptor agonist Frontiers The Role of Glucagon-Like Peptide-1

Providers should evaluate whether skin lightening aligns with your health goals and whether alternative, evidence-based dermatological options better suit your needs

There was no increased pancreatitis risk at 6 months, 1 year, 3 years, or 5 years

When Things Get More Serious The bigger concerns are rare, but they're worth knowing about

Research presented at the 2025 American Academy of Orthopaedic Surgeons meeting found GLP-1 users had approximately 30% higher rates of osteoporosis compared to non-users, and a 2024 phase 2 trial published in eClinicalMedicine showed increased bone resorption markers and lower bone mass at the spine and hip in the semaglutide group versus placebo after 52 weeks